IDO1 methylation by EZH2 confers resistance to its targeted therapy in colorectal cancer through tryptophan-kynurenine metabolic rewiring
Using a genome-wide CRISPR knockout screen and metabolomics, Tang et al. demonstrate that EZH2 blockade remodels tryptophan-kynurenine metabolism by upregulating IDO1.